Ardelyx Reaffirms 2026 IBSRELA Revenue Guidance and Targets 2027 Profitability
Ardelyx (ARDX) reported third-quarter revenue of over $125 million, representing a 19% increase compared to the previous year. During the earnings call, CEO Michael Raab outlined a strategic focus on accelerating the commercial growth of IBSRELA while maintaining the current market momentum for XPHOZAH. The company reaffirmed its long-term financial outlook, projecting annual revenue for IBSRELA to reach between $350 million and $370 million by 2026. Furthermore, management has set a strategic goal to achieve profitability by 2027 as they continue to expand their product pipeline.
Tickers: $ARDX
Topics: earnings report IBSRELA revenue growth XPHOZAH
Read the full article at Seeking Alpha
Part of the story MicroVision Reaffirms 2026 Revenue Guidance and Outlines 2027 Cash Burn Targets (11 articles)